Replies to post #125024 on Biotech Values

[DewDiligence]

FCSC—it's naive of you to think VRX would have no interest in a product that could be marketed to millions of acne scar sufferers with few other viable options.

VRX is looking for dermatology products it can sell. We can talk about acne scars when there are clinical data to show that laViv is safe and effective in that indication, which will be several years from now, if ever.

[Superfly15]

Why would VRX buy that POS when they can just let it starve and head to bankruptcy again? They do not and never will even have the manufacturing capacity to even be ABLE to sell the product if it was in high demand.